Boehringer Ingelheim and Re-Vana Therapeutics have announced a strategic collaboration and license agreement to develop first-in-class extended-release therapies for eye diseases.  Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients.   Re-Vana’s drug delivery technology is designed to release treatments slowly over six to 12 months, aiming […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!